Aktis Oncology Initiates Phase 1b Trial for AKY-2519 in Metastatic Prostate Cancer
summarizeSummary
Aktis Oncology announced the initiation of its Phase 1b clinical trial for AKY-2519, a B7-H3 miniprotein radioconjugate, in patients with metastatic castration-resistant prostate cancer (mCRPC). This follows the company's 10-K filing on March 30, 2026, which confirmed FDA clearance for AKY-2519 to enter Phase 1b trials, making this the official start of the clinical study. For a clinical-stage oncology company, advancing a second key candidate into Phase 1b is a material positive development, demonstrating pipeline progression and de-risking. The company also plans to initiate a second Phase 1b basket trial for AKY-2519 in other B7-H3 expressing solid tumors in the second half of 2026, with preliminary data from the mCRPC trial expected in 2027. Investors will be watching for updates on trial enrollment and the upcoming conference call to discuss the development strategy.
At the time of this announcement, AKTS was trading at $19.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $14.72 to $24.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.